There was more good news for Swiss company Roche (ROG: SIX) on Wednesday, as the US regulator’s scientific panel voted to maintain another Accelerated Approval for Tecentriq (atezolizumab).
The panel voted 10 to one in favor of keeping the approval, despite a lack of confirmatory data, for certain people with locally advanced or metastatic urothelial carcinoma, or bladder cancer.
On Tuesday the panel voted to keep another such early approval in place for the checkpoint blocker, in breast cancer. The Food and Drug Administration is expected to follow the recommendations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze